Capital World Investors 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-10-07 10:08 am Sale | 2024-10-07 | 13G | Revance Therapeutics, Inc. RVNC | Capital World Investors | 0 0.000% | -6,948,769 (Position Closed) | Filing |
| 2024-09-09 10:40 am Sale | 2024-09-09 | 13G | Revance Therapeutics, Inc. RVNC | Capital World Investors | 6,948,769 6.600% | -4,990,307 (-41.80%) | Filing |
| 2024-02-09 6:21 pm Purchase | 2024-02-07 | 13G | Revance Therapeutics, Inc. RVNC | Capital World Investors | 11,939,076 13.600% | 2,458,920 (+25.94%) | Filing |
| 2023-02-13 2:49 pm Purchase | 2023-02-14 | 13G | Revance Therapeutics, Inc. RVNC | Capital World Investors | 9,480,156 11.500% | 1,016,247 (+12.01%) | Filing |
| 2022-12-09 1:58 pm Purchase | 2022-12-12 | 13G | Revance Therapeutics, Inc. RVNC | Capital World Investors | 8,463,909 10.300% | 4,751,909 (+128.01%) | Filing |
| 2022-02-11 3:31 pm Purchase | 2022-02-14 | 13G | Revance Therapeutics, Inc. RVNC | Capital World Investors | 3,712,000 5.200% | 3,712,000 (New Position) | Filing |